John A. Ormiston
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
John A. Ormiston has a total of 241 co-authors. Here are the top co-authors by number of shared publications:
Mark W.I. Webster
From the Mercy Angiography, Auckland, New Zealand; Auckland City Hospital, New Zealand; and Department of Cardiology, University of Auckland School of Medicine, New Zealand
16 shared publicationsJames T. Stewart
10 shared publicationsPeter N. Ruygrok
10 shared publicationsBruce Webber
Interventional Cardiology Intra Healthcare 98 Mountain Road, Epsom Auckland 1023 New Zealand
5 shared publicationsMark Webster
5 shared publicationsDougal McClean
4 shared publications
Latest Publications
- 17 July 2020
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 97 (7) , E951-E955
Proximal to distal Y‐stenting for coronary bifurcation lesions using radial access: A modern bifurcation technique
Proximal to distal Y stenting technique is a modified bifurcation technique based on the original Y stenting technique described over 20 years ago. We use a bench top model to illustrate the steps of the technique, which can provide both provisional and full coverage options, using radial artery access. This technique may be applied in clinical settings on a wide range of bifurcation anatomies with a number of unique advantages.
- 17 July 2020
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 97 (7) , E951-E955
Proximal to distal Y‐stenting for coronary bifurcation lesions using radial access: A modern bifurcation technique
Proximal to distal Y stenting technique is a modified bifurcation technique based on the original Y stenting technique described over 20 years ago. We use a bench top model to illustrate the steps of the technique, which can provide both provisional and full coverage options, using radial artery access. This technique may be applied in clinical settings on a wide range of bifurcation anatomies with a number of unique advantages.
- 1 March 2018
- Published by Elsevier in Heart, Lung and Circulation
- Vol. 27 (3) , e11-e14
Transcatheter Aortic Valve Implantation In Patients With a Large Aortic Annulus
- 1 March 2018
- Published by Elsevier in Heart, Lung and Circulation
- Vol. 27 (3) , e11-e14
Transcatheter Aortic Valve Implantation In Patients With a Large Aortic Annulus
- 1 March 2018
- Published by Europa Digital & Publishing in EuroIntervention
- Vol. 13 (16) , 1876-1879
It seemed like a good idea at the time
The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)
- 1 March 2018
- Published by Europa Digital & Publishing in EuroIntervention
- Vol. 13 (16) , 1876-1879
It seemed like a good idea at the time
The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)
- Open Access
- 8 December 2017
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 92 (5) , 883-889
Coronary balloon catheter tip damage. A bench study of a clinical problem
To confirm clinically that coronary balloon catheter tips may be damaged during bifurcation treatment with side-branch access through the side of a stent. On the bench, we aimed to assess the susceptibility of different balloon designs to damage. We compared catheter tip widths. We tested whether balloon tip flaring can cause stent distortion. We had observed that balloon catheters that failed to cross to a side-branch frequently exhibited tip damage. We examined microscopically for damage 82 balloon tips after clinical side-branch access. In a bench study, the forces required to compress catheter tips 0.5 mm were compared to assess susceptibility to damage. We compared tip widths of balloons of different nominal inflation diameters. We examined stents after side-branch access for distortion. In 42 of 48 (88%) of balloon tips from patients with resistance to or failure to cross through the side of a stent there was tip damage. Even when the balloon crossed without perceptible resistance, tip damage occurred in over half of balloons 18/34 (53%). Some balloon designs were more resistant to damage than others. Tips from balloons of different nominal diameters from the same manufacturer had the same width. Stent distortion caused by damaged balloon tips is improved by kissing balloon post-dilatation. Balloon tip damage is common with crossing between stent struts. This is one cause of failure of a balloon to access a side-branch and a new balloon should be used. If stent distortion is suspected, it should be corrected with kissing balloon post-dilatation.
- 8 December 2017
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 92 (5) , 883-889
Open AccessCoronary balloon catheter tip damage. A bench study of a clinical problem
To confirm clinically that coronary balloon catheter tips may be damaged during bifurcation treatment with side-branch access through the side of a stent. On the bench, we aimed to assess the susceptibility of different balloon designs to damage. We compared catheter tip widths. We tested whether balloon tip flaring can cause stent distortion. We had observed that balloon catheters that failed to cross to a side-branch frequently exhibited tip damage. We examined microscopically for damage 82 balloon tips after clinical side-branch access. In a bench study, the forces required to compress catheter tips 0.5 mm were compared to assess susceptibility to damage. We compared tip widths of balloons of different nominal inflation diameters. We examined stents after side-branch access for distortion. In 42 of 48 (88%) of balloon tips from patients with resistance to or failure to cross through the side of a stent there was tip damage. Even when the balloon crossed without perceptible resistance, tip damage occurred in over half of balloons 18/34 (53%). Some balloon designs were more resistant to damage than others. Tips from balloons of different nominal diameters from the same manufacturer had the same width. Stent distortion caused by damaged balloon tips is improved by kissing balloon post-dilatation. Balloon tip damage is common with crossing between stent struts. This is one cause of failure of a balloon to access a side-branch and a new balloon should be used. If stent distortion is suspected, it should be corrected with kissing balloon post-dilatation.
- 1 August 2016
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 9 (8)
Of Stents and Scaffolds
- 1 August 2016
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 9 (8)
Of Stents and Scaffolds
- 1 June 2016
- Published by Elsevier in Journal of Biomechanics
- Vol. 49 (9) , 1570-1582
Impact of bifurcation angle and other anatomical characteristics on blood flow – A computational study of non-stented and stented coronary arteries
- 1 June 2016
- Published by Elsevier in Journal of Biomechanics
- Vol. 49 (9) , 1570-1582
Impact of bifurcation angle and other anatomical characteristics on blood flow – A computational study of non-stented and stented coronary arteries
- 6 May 2016
- Vol. 64 (5) , 560-71
Technical overview on the MiStent coronary stent.
Drug-eluting stents (DES) have dramatically improved the long-term efficacy of percutaneous coronary intervention (PCI). Over the last decade there have been numerous advances in DES platforms, however, all but one currently approved DES in the United States and many of the approved DES worldwide still have 3 common features: a metal stent platform, an anti-proliferative drug, and a permanent polymer. In this context, the polymer is critical to control drug release, but the polymer serves no purpose after the drug is eluted. While designed to be completely biocompatible, synthetic polymers have the potential to illicit an inflammatory response within the vessel including but not limited to delayed healing and hypersensitivity. Adverse vascular reactions to these polymers have been implicated as a cause of very late stent thrombosis, ongoing intimal hyperplasia and late "catch-up" in addition to neoatherosclerosis. To avoid the long-term risks associated with prolonged polymer exposure, DES with bioabsorbable polymers have been developed. The MiStent® Sirolimus-Eluting Absorbable Polymer Coronary Stent System (MiStent SES) (MiCell Technologies, Durham, NC, USA) combines crystalline sirolimus, a rapidly absorbing polylactide-co-glycolic acid (PLGA) coating and a thin-strut cobalt chromium alloy stent platform (Genius MAGIC® Stent System, EuroCor GmbH, Germany). MiCell's supercritical fluid technology allows a rigorously controlled, solvent-free drug and polymer coating to be applied to a bare-metal stent. This solvent-free application of drug uniquely allows a crystalline form of sirolimus to be used on the MiStent SES potentially providing improved clinical benefits. It avoids the uncontrolled burst of drug seen with other DES, provides uniform drug delivery around and between the stent struts, and allows the anti-inflammatory and anti-restenotic drug (sirolimus) to be present in the tissue through the entire polymer absorption period and for months after the polymer has been absorbed. On the MiStent SES, the PLGA/crystalline sirolimus combination is cleared from the stent within 45-60 days and PLGA is fully absorbed within 90 days. The crystalline form of sirolimus uniquely remains in the tissue and continues to expose the surrounding tissue to therapeutic levels of drug for up to 9 months which is long after the polymer is resorbed.
- 6 May 2016
- Vol. 64 (5) , 560-71
Technical overview on the MiStent coronary stent.
Drug-eluting stents (DES) have dramatically improved the long-term efficacy of percutaneous coronary intervention (PCI). Over the last decade there have been numerous advances in DES platforms, however, all but one currently approved DES in the United States and many of the approved DES worldwide still have 3 common features: a metal stent platform, an anti-proliferative drug, and a permanent polymer. In this context, the polymer is critical to control drug release, but the polymer serves no purpose after the drug is eluted. While designed to be completely biocompatible, synthetic polymers have the potential to illicit an inflammatory response within the vessel including but not limited to delayed healing and hypersensitivity. Adverse vascular reactions to these polymers have been implicated as a cause of very late stent thrombosis, ongoing intimal hyperplasia and late "catch-up" in addition to neoatherosclerosis. To avoid the long-term risks associated with prolonged polymer exposure, DES with bioabsorbable polymers have been developed. The MiStent® Sirolimus-Eluting Absorbable Polymer Coronary Stent System (MiStent SES) (MiCell Technologies, Durham, NC, USA) combines crystalline sirolimus, a rapidly absorbing polylactide-co-glycolic acid (PLGA) coating and a thin-strut cobalt chromium alloy stent platform (Genius MAGIC® Stent System, EuroCor GmbH, Germany). MiCell's supercritical fluid technology allows a rigorously controlled, solvent-free drug and polymer coating to be applied to a bare-metal stent. This solvent-free application of drug uniquely allows a crystalline form of sirolimus to be used on the MiStent SES potentially providing improved clinical benefits. It avoids the uncontrolled burst of drug seen with other DES, provides uniform drug delivery around and between the stent struts, and allows the anti-inflammatory and anti-restenotic drug (sirolimus) to be present in the tissue through the entire polymer absorption period and for months after the polymer has been absorbed. On the MiStent SES, the PLGA/crystalline sirolimus combination is cleared from the stent within 45-60 days and PLGA is fully absorbed within 90 days. The crystalline form of sirolimus uniquely remains in the tissue and continues to expose the surrounding tissue to therapeutic levels of drug for up to 9 months which is long after the polymer is resorbed.
- Open Access
- 16 July 2015
- Published by Springer Nature in Annals of Biomedical Engineering
- Vol. 44 (2) , 315-329
Hemodynamics in Idealized Stented Coronary Arteries: Important Stent Design Considerations
Stent induced hemodynamic changes in the coronary arteries are associated with higher risk of adverse clinical outcome. The purpose of this study was to evaluate the impact of stent design on wall shear stress (WSS), time average WSS, and WSS gradient (WSSG), in idealized stent geometries using computational fluid dynamics. Strut spacing, thickness, luminal protrusion, and malapposition were systematically investigated and a comparison made between two commercially available stents (Omega and Biomatrix). Narrower strut spacing led to larger areas of adverse low WSS and high WSSG but these effects were mitigated when strut size was reduced, particularly for WSSG. Local hemodynamics worsened with luminal protrusion of the stent and with stent malapposition, adverse high WSS and WSSG were identified around peak flow and throughout the cardiac cycle respectively. For the Biomatrix stent, the adverse effect of thicker struts was mitigated by greater strut spacing, radial cell offset and flow-aligned struts. In conclusion, adverse hemodynamic effects of specific design features (such as strut size and narrow spacing) can be mitigated when combined with other hemodynamically beneficial design features but increased luminal protrusion can worsen the stent’s hemodynamic profile significantly.
- 16 July 2015
- Published by Springer Nature in Annals of Biomedical Engineering
- Vol. 44 (2) , 315-329
Open AccessHemodynamics in Idealized Stented Coronary Arteries: Important Stent Design Considerations
Stent induced hemodynamic changes in the coronary arteries are associated with higher risk of adverse clinical outcome. The purpose of this study was to evaluate the impact of stent design on wall shear stress (WSS), time average WSS, and WSS gradient (WSSG), in idealized stent geometries using computational fluid dynamics. Strut spacing, thickness, luminal protrusion, and malapposition were systematically investigated and a comparison made between two commercially available stents (Omega and Biomatrix). Narrower strut spacing led to larger areas of adverse low WSS and high WSSG but these effects were mitigated when strut size was reduced, particularly for WSSG. Local hemodynamics worsened with luminal protrusion of the stent and with stent malapposition, adverse high WSS and WSSG were identified around peak flow and throughout the cardiac cycle respectively. For the Biomatrix stent, the adverse effect of thicker struts was mitigated by greater strut spacing, radial cell offset and flow-aligned struts. In conclusion, adverse hemodynamic effects of specific design features (such as strut size and narrow spacing) can be mitigated when combined with other hemodynamically beneficial design features but increased luminal protrusion can worsen the stent’s hemodynamic profile significantly.